Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Southwest Oncology Group
Sponsor:
Collaborators:
AstraZeneca
Novartis
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT02137837
First received: May 12, 2014
Last updated: August 19, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2018
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)